Overview

A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction induced by environmental cat dander exposure in patients 18-65 years old with stable, moderate asthma and a history of cat dander-induced asthma symptoms.

Phase:

Phase 4

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Omalizumab